Epic Wound Care enters beta test agreement with Ryan Network for UEEC's hemostatic gauze

Published on February 15, 2013 at 7:35 AM · No Comments

United Health Products, Inc.'s www.unitedhealthproductsinc.com (OTCQB: UEEC.PK) wholly owned subsidiary, Epic Wound Care, Inc., which develops and markets products and technologies in the healthcare sector, is pleased to announce that it has entered into a beta test agreement with the distinguished Ryan Network for UEEC's hemostatic gauze. The gauze is registered and branded in the USA under the trademark HemoStyp™. Under the beta test protocol, the HemoStyp™ gauze will be indicated for patients post venipuncture to assess expedited coagulation, ease of use, patient satisfaction, and decrease prolonged coagulation due to patients co-morbidities and anticoagulation therapy. The Ryan Network was founded upon former Congressman William F. Ryan's belief that "health care is a right, not a privilege." Ryan Network is a family of not-for-profit, federally qualified health centers with multiple locations in New York City. In July 2011, medical residents and attending preceptor physicians from St. Luke's-Roosevelt Hospital Center (SLRHC) began providing front-line primary medical care in Ryan's Adult Medicine Department as part of their training in the Medical Residency Program/SLRHC. The Network's other sites, Ryan-NENA (2011 - Beth Israel Hospital), Ryan Chelsea-Clinton (2007 - Roosevelt Hospital) and Ryan/Adair (2009 - SLRHC), also have medical residents in place (in some cases, for several years), to the mutual benefit of Ryan's patients and the Medical Residency Program. The Network's service sites also include the new Ryan Women & Children's Center, clinics at four family living transitional shelters, one rehabilitation center and six school-based health centers. The service sites are fully coordinated with all services at the main center sites.

HemoStyp™ is a gauze specifically formulated to produce hemostasis almost instantly when positioned on a cut or wound. It contains no potentially harmful chemicals such as thrombin, collagen or animal byproducts, is hypoallergenic and works more quickly than other hemostatic agents. Once it has completed its task, it is readily dissolved by saline solution or water for easy removal that neither disturbs the clotted surface nor encourages re-bleeding.

Dr. Phillip Forman, CEO of United Health Products Inc., stated, "The Ryan Network delivers world-class medical care to diverse and underserved communities, and their commitment to the beta testing is one more way they can deliver on that promise to those communities." Dr. Forman hoped to have the results of the specific study parameters and data collection available within 60 days.

Source:

United Health Products, Inc.

Posted in: Device / Technology News | Healthcare News

Tags: , , , ,

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
State highlights: Calif. hospital bid draws scrutiny; hospital house calls